Skip to content

Chongqing Diabetes Registry Study

Chongqing Diabetes and Its Chronic Complications Registry Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03692884
Acronym
CDR
Enrollment
5000
Registered
2018-10-02
Start date
2018-07-01
Completion date
2030-07-01
Last updated
2023-09-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus

Keywords

diabetes mellitus, risk factors, biomarkers, chronic diabetes complications

Brief summary

To investigate the risk factors and biomarkers of the microvascular disease,macrovascular disease and neuropathy in patients with diabetes.

Detailed description

This study is a prospective cohort study. About 5000 patients with diabetes from the Chongqing Diabetes Centre,Chongqing,China, will be enrolled for long-term follow-up.Information on socio-demographic parameters, medical history, current drug use,lifestyle factors, anthropometric measurements, metabolic control indicators and diabetes complications examination will be documented. Blood and urine samples will be collected. This study aimed to assess risk factors and biomarkers of occurrence and development of diabetic microvascular disease,macrovascular disease and neuropathy in patients with diabetes.

Interventions

None listed

Sponsors

Chongqing Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

1. Diagnosis of diabetes mellitus(based on the 1999 WHO diagnostic cretirial); 2. Age younger than 75 years old, gender is not limited; 3. Voluntary to sign on the informed consent.

Exclusion criteria

1. pregnant or breast-feeding women; 2. Patients with chronic disease requiring long-term glucocorticoid therapy; 3. Patients with severe infection (except for diabetic foot) or immune dysfunction.

Design outcomes

Primary

MeasureTime frameDescription
The number of patients whoes Diabetic Kidney disease (DKD) is worsen5 yearsWorsen DKD is defined as Urine Albumin Creatinine Ratio (UACR)\> 300 mg/g Cr(twice out of three measures), or 24 hours urinary protein\> 300 mg / 24 h, or double serum creatinine level and at least 200μmol/l (2.26 mg/dl), or require renal replacement therapy, or death due to kidney disease.

Secondary

MeasureTime frameDescription
The number of patients who develop Diabetic Retinopathy5 yearsNew Diabetic Retinopathy
The number of patients whoes DR is worsen5 yearsWorsen DKD is defined as any eye with original Diabetic Rretinopathy aggravated by at least one level, or progress to proliferation retinopathy, or appearance of macular degeneration, or at least one eye with blindness (refer to the WHO standards, the Snellen-chart vision drop to 6/60 or less), or to accept retinal photocoagulation treatment, or accept vitrectomy.
The number of patients who develop DKD5 yearsDiabetic Kidney Disease is defined as UACR \> 30 mg/g Cr(twice out of three measures),or estimated Glomerular Filtration Rate(eGFR)\<60ml/min/1.73m2.
The number of patients who develop Cardiovascular events10 yearsCardiovascular events are difined as death of cardiovascular events, or non-fatal myocardial infarction, or non-fatal stroke, or revascularization procedure (cardiac, carotid, or peripheral), or hospitalization for heart failure.
The number of patients who develop Diabetic foot10 yearsDiabetic foot was defined as active diabetic foot problem: ulceration, spreading infection, critical ischaemia, gangrene, suspicion of an acute Charcot arthropathy, or an unexplained hot, red, swollen foot with or without pain.
The number of patients who develop Diabetic Neuropathy5 yearsDiabetic Peripheral Neuropathy is defined as Neuropathy Symptom Score/Neuropathy Disability Score(NSS/NDS) with at least two positive outcomes, or electromyography examination to identify nerve damage;Diabetic Autonomic Neuropathy is defined as tachycardia at rest (Heart Ratio\>100bpm) and postural hypotension (standing position leads systolic blood pressure reduction \>20mmHg).

Countries

China

Contacts

Primary ContactQifu Li, phD
liqifu@yeah.net+86 023-89011552
Backup ContactZhihong Wang, phD
towzh713@126.com+86 023-89011552

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 22, 2026